Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Using a national surveillance network, a team of researchers at Cambridge Health Alliance tracked emergency room visits linked to semaglutide in 82 different hospitals over a two-year period.

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended. At Melrose ...

Researchers examined 1733 reports of ocular adverse drug events, comprising 1541 and 192 cases related to injectable forms and oral tablets ... both formulations of semaglutide; adverse drug ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...